{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T07:09:00Z","timestamp":1742800140130},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.berh.2010.01.007","type":"journal-article","created":{"date-parts":[[2010,8,22]],"date-time":"2010-08-22T04:38:42Z","timestamp":1282451922000},"page":"497-511","source":"Crossref","is-referenced-by-count":5,"title":["Treating to re-establish tolerance in inflammatory arthritis \u2013 lessons from other diseases"],"prefix":"10.1016","volume":"24","author":[{"given":"Faye A.H.","family":"Cooles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8998","key":"10.1016\/j.berh.2010.01.007_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(96)90535-8","article-title":"Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis","volume":"347","author":"ten Wolde","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2010.01.007_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.iy.07.040189.002203","article-title":"Manipulation of T-cell responses with monoclonal antibodies","volume":"7","author":"Waldmann","year":"1989","journal-title":"Annu Rev Immunol"},{"issue":"5097","key":"10.1016\/j.berh.2010.01.007_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.8094901","article-title":"\u201cInfectious\u201d transplantation tolerance","volume":"259","author":"Qin","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.berh.2010.01.007_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1996.tb00897.x","article-title":"Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8","volume":"149","author":"Cobbold","year":"1996","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar1983","article-title":"Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity","volume":"8","author":"van der Helm-van Mil","year":"2006","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.berh.2010.01.007_bib6","series-title":"Immune tolerance: Jenner, Pasteur and their successors","article-title":"How may immunosuppression lead to tolerance? The war analogy","author":"Waldmann","year":"1997"},{"issue":"1","key":"10.1016\/j.berh.2010.01.007_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd2196","article-title":"Biologic therapies in rheumatology: lessons learned, future directions","volume":"6","author":"Strand","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.berh.2010.01.007_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0140-6736(92)92294-P","article-title":"Humanised monoclonal antibody therapy for rheumatoid arthritis","volume":"340","author":"Isaacs","year":"1992","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"CAMPATH-1H in rheumatoid arthritis\u2013an intravenous dose-ranging study","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.berh.2010.01.007_bib10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T","article-title":"Morbidity and mortality in rheumatoid arthritis patients with profound and prolonged therapy-induced lymphopenia","volume":"44","author":"Isaacs","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/art.23122","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes","volume":"58","author":"Lorenzi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4961","key":"10.1016\/j.berh.2010.01.007_bib12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.2113314","article-title":"A cell culture model for T lymphocyte clonal anergy","volume":"248","author":"Schwartz","year":"1990","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2010.01.007_bib14","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/eji.1830201232","article-title":"The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies","volume":"20","author":"Cobbold","year":"1990","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.berh.2010.01.007_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.intimp.2004.09.026","article-title":"Prope tolerance\u2013the future of organ transplantation from the laboratory to the clinic","volume":"5","author":"Calne","year":"2005","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"10.1016\/j.berh.2010.01.007_bib16","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.4049\/jimmunol.178.9.5419","article-title":"Clinical transplantation tolerance: many rivers to cross","volume":"178","author":"Salama","year":"2007","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.berh.2010.01.007_bib17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1432-2277.2008.00783.x","article-title":"Clinical experience with mixed chimerism to induce transplantation tolerance","volume":"21","author":"Fehr","year":"2008","journal-title":"Transpl Int"},{"issue":"7","key":"10.1016\/j.berh.2010.01.007_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri2568","article-title":"Towards the identification of biomarkers of transplantation tolerance","volume":"9","author":"Turka","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/qjmed\/hcn006","article-title":"A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis","volume":"101","author":"Morgan","year":"2008","journal-title":"Quarterly Journal of Medicine"},{"key":"10.1016\/j.berh.2010.01.007_bib20","series-title":"The Immune Synapse as a Novel Target for Therapy","first-page":"169","article-title":"From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic","author":"Ng","year":"2008"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007890-200008150-00005","article-title":"Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction","volume":"70","author":"Smiley","year":"2000","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","article-title":"Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells","volume":"107","author":"Coenen","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2337\/db08-1432","article-title":"Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice","volume":"58","author":"Valle","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.berh.2010.01.007_bib24","first-page":"121","article-title":"The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation","volume":"174","author":"Chatenoud","year":"1991","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1000","article-title":"CD3-specific antibody-induced active tolerance: from bench to bedside","volume":"3","author":"Chatenoud","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.berh.2010.01.007_bib26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coi.2005.09.011","article-title":"CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications","volume":"17","author":"Chatenoud","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"22","key":"10.1016\/j.berh.2010.01.007_bib27","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2010.01.007_bib28","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2010.01.007_bib29","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clim.2009.04.007","article-title":"Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years","volume":"132","author":"Herold","year":"2009","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI16090","article-title":"Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)","volume":"111","author":"Herold","year":"2003","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib33","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI23961","article-title":"TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs","volume":"115","author":"Bisikirska","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2009.09.005","article-title":"Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies","volume":"134","author":"Cernea","year":"2010","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI27191","article-title":"Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs","volume":"116","author":"Bresson","year":"2006","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib37","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.4049\/jimmunol.179.5.3325","article-title":"Cytokine Storm' in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics","volume":"179","author":"Stebbings","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2010.01.007_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/brain\/119.1.225","article-title":"Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis","volume":"119","author":"Moreau","year":"1996","journal-title":"Brain"},{"issue":"39","key":"10.1016\/j.berh.2010.01.007_bib39","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1073\/pnas.0808248105","article-title":"In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner","volume":"105","author":"Albert","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib40","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Plevy","year":"2007","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.berh.2010.01.007_bib41","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"issue":"9191","key":"10.1016\/j.berh.2010.01.007_bib42","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.berh.2010.01.007_bib43","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2010.01.007_bib44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"5 Pt 1","key":"10.1016\/j.berh.2010.01.007_bib45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","article-title":"Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab","volume":"6","author":"Kirk","year":"2006","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beha.2006.09.008","article-title":"Autoimmunity following haematopoietic stem-cell transplantation","volume":"20","author":"Daikeler","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"10.1016\/j.berh.2010.01.007_bib47","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib48","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: role of immunosuppressive drugs","volume":"18","author":"Noris","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.berh.2010.01.007_bib49","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.177.2.944","article-title":"Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells","volume":"177","author":"Valmori","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.berh.2010.01.007_bib50","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.berh.2010.01.007_bib51","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1398-9995.2005.00885.x","article-title":"The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects","volume":"60","author":"Alexander","year":"2005","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib53","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1371\/journal.pmed.0020078","article-title":"T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity","volume":"2","author":"Verhoef","year":"2005","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.berh.2010.01.007_bib54","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.20082901","article-title":"Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression","volume":"206","author":"Campbell","year":"2009","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/dmrr.942","article-title":"Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results","volume":"25","author":"Eldor","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib56","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.22567","article-title":"Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis","volume":"56","author":"Massa","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2010.01.007_bib57","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.24656","article-title":"Pan-DR-binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis","volume":"60","author":"de Jong","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/intimm\/dxl074","article-title":"Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis","volume":"18","author":"Nussbaum","year":"2006","journal-title":"Int Immunol"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib59","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2010.01.007_bib60","article-title":"Intranasal administration of recombinant Human Cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: A Phase II, multicenter, double-blind, randomized, placebo-controlled, parallel group dose-finding trial","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2010.01.007_bib61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrd2956","article-title":"Retuning the immune system: the future of type 1 diabetes therapy?","volume":"8","author":"Jones","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib62","first-page":"482","article-title":"Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR","volume":"31","author":"Snowden","year":"2004","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib63","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.berh.2010.01.007_bib64","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2010.01.007_bib65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib66","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib67","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/ard.2004.033332","article-title":"Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration","volume":"64","author":"Verburg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2010.01.007_bib68","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1182\/blood-2002-03-0671","article-title":"Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis","volume":"100","author":"Ponchel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.berh.2010.01.007_bib69","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar1452","article-title":"Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia","volume":"7","author":"Ponchel","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2010.01.007_bib70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.berh.2010.01.007_bib71","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20042321","article-title":"Impaired early B cell tolerance in patients with rheumatoid arthritis","volume":"201","author":"Samuels","year":"2005","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.berh.2010.01.007_bib72","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.20452","article-title":"Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease","volume":"50","author":"Pavletic","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.seminhematol.2007.04.009","article-title":"Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation","volume":"44","author":"Seggewiss","year":"2007","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib74","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4049\/jimmunol.175.5.3053","article-title":"Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice","volume":"175","author":"Masteller","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2010.01.007_bib75","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"Journal of Experimental Medicine"},{"issue":"12","key":"10.1016\/j.berh.2010.01.007_bib76","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.4049\/jimmunol.181.12.8209","article-title":"Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease","volume":"181","author":"Huter","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2010.01.007_bib77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/08830180903281193","article-title":"Development of dendritic cell-based immunotherapy for autoimmunity","volume":"29","author":"Hilkens","year":"2010","journal-title":"International Reviews of Immunology"},{"key":"10.1016\/j.berh.2010.01.007_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.2009.04607.x","article-title":"Mesenchymal stromal cells","volume":"1176","author":"Bernardo","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"10.1016\/j.berh.2010.01.007_bib79","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood-2008-07-144485","article-title":"The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology","volume":"113","author":"Curti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.berh.2010.01.007_bib80","article-title":"Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis","author":"Gonzalez-Rey","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2010.01.007_bib81","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/art.24405","article-title":"Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells","volume":"60","author":"Gonzalez","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9624","key":"10.1016\/j.berh.2010.01.007_bib82","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2010.01.007_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jcp.21915","article-title":"Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering","volume":"222","author":"Richardson","year":"2010","journal-title":"Journal of Cell Physiology"},{"issue":"5","key":"10.1016\/j.berh.2010.01.007_bib84","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"van Dongen","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2010.01.007_bib85","doi-asserted-by":"crossref","first-page":"p510","DOI":"10.1136\/ard.2009.119016","article-title":"The impact of T-cell co-stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2010.01.007_bib86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"Quinn","year":"2005","journal-title":"Arth Rheum"},{"issue":"1","key":"10.1016\/j.berh.2010.01.007_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J Exp Med"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694210000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694210000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T11:57:36Z","timestamp":1544270256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694210000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1521694210000082"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2010.01.007","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}